GBIM from IV.Msg 97 of 97 at 3/16/2016 10:03:12 AM by
wbart21
report abuse recommend
In response to msg 96 by buygene view thread
Re: GlobeImmune Announces Updates and Financial Results for Full Year 2015
$9.9mm is about $1mm more than i thought. One less scientist,so only 3 employees w/ CEO taking 50% of salary= minimal burn going forward and most importantly, GILD has agreed to release 24week primary endpoint data on GS-4774 in Q2 ! Can't believe GILD would make a go no-go decision in Q2 rather than awaiting the full 48 week data set.
Obviously the million dollar question is.... is the move up of 24 week data to Q2 an attempt by gbim(GILD obviously had to agree)to search for some evidence of effect @ 24 weeks to drive a better strategic transaction and save the company or because this is an OLS do gild/gbim already have some good 24 data points in hand. As JT pointed out on twtr, EASL is a mere 4 weeks away. Stock is an easy hold here,irrespective , as they have almost $10mm cash, 3 employees, still retain Cantor and if 4774 fails, they still have CELG MTC P2 readout later this year and the Chordoma trial w/ CELG/NCR- so 2 more shots on goal ;)
